OCI-AML4

human (Homo sapiens)

acute myeloid leukemia

established in 1987 from the blast cells of the peripheral blood of a 35-year-old woman with acute myeloblastic leukemia (AML M4), secondary to the treatment of nodular sclerosing Hodgkin disease with radiation and chemotherapy; cells were described in the literature to grow slowly with stimulation but responds to IL-3, GM-CSF and mast cell growth factor (MGF); cells exhibit wild-type TP53

16846, 16847

1

A

Transfer to third parties needs to be negotiated with the depositor.

round to polymorphic cells growing singly or in clumps in suspension, some cells are adherent; image; image; image; image; image

80% alpha-MEM (with ribo- and deoxyribonucleosides) + 20% h.i. FBS

seed out at ca. 0.5 x 10⁶ cells/ml; maintain at ca. 0.5-1.5 x 10⁶ cells/ml; optimal split ratio 1:2 to 1:4 every 2-4 days

at 37 °C with 5% CO₂

ca. 24-30 hours

maximum density at ca. 2 x 10⁶ cells/ml

frozen with 70% medium, 20% FBS, 10% DMSO

negative in microbiological culture, PCR assays

CD3 -, CD4 +, CD13 +, CD14 -, CD15 -, CD33 +, HLA-DR +; image

STR analysis according to the global standard ANSI/ATCC ASN-0002.1-2021 (2021) resulted in an authentic STR profile of the reference STR database.

human flat moded near diploid karyotype with 3% polyploidy; -46(43-47)<2n>XX, der(6)(3qter->3q27::3q26->3q25::6p21->6q27::3q26->3q27::3q26->3qter), der(11)t(11;19)(q23;p13.3), der(16)t(1;16)(q22;p13), der(18)dup(18)(q11q23.2)t(X;18)(p22;q23.3), der(19)t(8;19)(q12;p13.1), der(22)t(11;22)(q23;q22)t(11;19)(q23;p13.3); carries semi-cryptic t(11;19) effecting rearrangement of KMT2A (MLL) with MLLT1 (ENL)

PCR: EBV -, HBV -, HCV -, HIV-1 -, HIV-2 -, HTLV-I/-II -, MLV -

Delivery form		Prices
Frozen culture		450,- €
Growing culture   (please inquire for exact delivery time)		900,- €
DNA isolated from cell line (25 µg)		560,- €
DNA isolated from cell line (5 µg)		140,- €

see price list

Print data sheet